Get the Stockscreener App
0.8347
2.20%
-0.0188
Oncolytics Biotech Inc stock is traded at $0.8347, with a volume of 779.22K.
It is down -2.20% in the last 24 hours and down -15.82% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$0.8535
Open:
$0.85
24h Volume:
779.22K
Relative Volume:
0.76
Market Cap:
$89.82M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-3.1558
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
-0.23%
1M Performance:
-15.82%
6M Performance:
-2.98%
1Y Performance:
+6.82%
1-Day Range:
$0.819
$0.86
1-Week Range:
$0.789
$0.9076
52-Week Range:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.8347 | 91.84M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Oncolytics Biotech (NASDAQ:ONCY) Trading 1.3% HigherHere's Why - MarketBeat
Precision Biologics Market Awakens to $71 Billion Opportunity - Intellectia AI
New Highs: How sensitive is Oncolytics Biotech Inc to inflation2025 Bull vs Bear & Safe Capital Growth Stock Tips - baoquankhu1.vn
Oncolytics Biotech Forms Advisory Board to Advance Pelareorep in GI Cancers - MSN
Oncolytics Biotech Receives FDA Fast Track Designation - Intellectia AI
$207B Market Shift: The Race for Fast Track Approval in Oncology - Investing News Network
Oncolytics Biotech Inc - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - Barchart.com
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up - GlobeNewswire
Oncolytics receives FDA Fast Track Designation for pelareorep - Yahoo Finance
ONCY stock rallies on second fast track designation for experimental cancer drug - MSN
Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Yahoo Finance
Oncolytics Biotech receives FDA Fast Track for pelareorep - TipRanks
Oncolytics Biotech Inc Receives FDA Fast Track Designation for Pelareorep - TradingView
ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug - Stocktwits
Oncolytics Biotech receives FDA fast track designation for pelareorep in 2L KRAS-mutant MSS metastatic colorectal cancer - marketscreener.com
Oncolytics Biotech (ONCY) Secures FDA Fast Track for Cancer Trea - GuruFocus
Oncolytics surges on Fast Track status for pelareorep in colorectal cancer - Seeking Alpha
Oncolytics Biotech stock soars after FDA grants Fast Track Designation By Investing.com - Investing.com South Africa
Oncolytics Biotech stock soars after FDA grants Fast Track Designation - Investing.com
Oncolytics (ONCY) Secures FDA Fast Track for Innovative Cancer T - GuruFocus
Oncolytics Biotech Showcases Promising Immunotherapy Advancements - timothysykes.com
FDA grants fast track designation to Oncolytics’ pelareorep for colorectal cancer - Investing.com
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer - The Manila Times
Oncolytics Biotech Receives Fast Track Designation for Pelareorep in Second-Line KRAS-Mutant MSS Metastatic Colorectal Cancer Following Promising Clinical Data - Quiver Quantitative
Oncolytics Biotech® Receives FDA Fast Track Designation for - GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Investment Review: Does Entergy Texas Inc have a sustainable dividendJuly 2025 Snapshot & Safe Swing Trade Setup Alerts - baoquankhu1.vn
EPS Watch: Can Oncolytics Biotech Inc expand its profit marginsQuarterly Trade Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Stock Report: Is Oncolytics Biotech Inc forming a breakout pattern - baoquankhu1.vn
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors - The Globe and Mail
Record $2.5B Sector Start Spotlights Clinical Oncology Plays - Baystreet.ca
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium - PR Newswire
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment - The Globe and Mail
Late-Stage Breakthroughs: How 2026’s Top Clinical Platforms Are Redefining Cancer Treatment - Cantech Letter
Registration-Ready: How 2026’s Clinical Leaders Are Beating Cancer Benchmarks - Cantech Letter
Performance Recap: What is Oncolytics Biotech Incs 5 year growth outlookJuly 2025 Macro Moves & Community Consensus Trade Alerts - baoquankhu1.vn
Oncolytics Biotech Strengthens Leadership Amid Oncology Market Surge - Intellectia AI
Oncolytics Biotech Strengthens Leadership for Oncology Trials - Intellectia AI
Hard-to-Treat Cancers: How 2026’s Top Clinical Platforms Are Beating Industry Benchmarks - Baystreet.ca
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks - Newswire Canada
THE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack - The Globe and Mail
Trade Recap: What analysts say about SFBS stockBreakout Watch & Weekly High Return Forecasts - baoquankhu1.vn
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY) - The Globe and Mail
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):